135 related articles for article (PubMed ID: 38335967)
1. Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite.
Hu H; Serra C; Zhang W; Scrivo A; Fernández-Carasa I; Consiglio A; Aytes A; Pujana MA; Llebaria A; Antolin AA
Cell Chem Biol; 2024 May; 31(5):973-988.e4. PubMed ID: 38335967
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of
Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
[TBL] [Abstract][Full Text] [Related]
3. Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib.
Kossatz S; Carney B; Farley C; Weber WA; Drain CM; Reiner T
J Nucl Med; 2018 Aug; 59(8):1316-1320. PubMed ID: 29572258
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
Augustine T; Maitra R; Zhang J; Nayak J; Goel S
Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of absorption, distribution, metabolism, and excretion of [
Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
[TBL] [Abstract][Full Text] [Related]
6. The kinase polypharmacology landscape of clinical PARP inhibitors.
Antolin AA; Ameratunga M; Banerji U; Clarke PA; Workman P; Al-Lazikani B
Sci Rep; 2020 Feb; 10(1):2585. PubMed ID: 32066817
[TBL] [Abstract][Full Text] [Related]
7. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
[TBL] [Abstract][Full Text] [Related]
8. Strategies Employed for the Development of PARP Inhibitors.
Canan S; Maegley K; Curtin NJ
Methods Mol Biol; 2017; 1608():271-297. PubMed ID: 28695516
[TBL] [Abstract][Full Text] [Related]
9. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.
Palve V; Knezevic CE; Bejan DS; Luo Y; Li X; Novakova S; Welsh EA; Fang B; Kinose F; Haura EB; Monteiro AN; Koomen JM; Cohen MS; Lawrence HR; Rix U
Cell Chem Biol; 2022 Feb; 29(2):202-214.e7. PubMed ID: 34329582
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS.
Almeida GS; Bawn CM; Galler M; Wilson I; Thomas HD; Kyle S; Curtin NJ; Newell DR; Maxwell RJ
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28543772
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Cho HY; Kim YB; Park WH; No JH
Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
[TBL] [Abstract][Full Text] [Related]
12. Novel pharmacological effects of poly (ADP-ribose) polymerase inhibitor rucaparib on the lactate dehydrogenase pathway.
Nonomiya Y; Noguchi K; Katayama K; Sugimoto Y
Biochem Biophys Res Commun; 2019 Mar; 510(4):501-507. PubMed ID: 30737031
[TBL] [Abstract][Full Text] [Related]
13. Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.
Karpova Y; Wu C; Divan A; McDonnell ME; Hewlett E; Makhov P; Gordon J; Ye M; Reitz AB; Childers WE; Skorski T; Kolenko V; Tulin AV
Biochem Pharmacol; 2019 Sep; 167():149-162. PubMed ID: 30880062
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
Ihnen M; zu Eulenburg C; Kolarova T; Qi JW; Manivong K; Chalukya M; Dering J; Anderson L; Ginther C; Meuter A; Winterhoff B; Jones S; Velculescu VE; Venkatesan N; Rong HM; Dandekar S; Udar N; Jänicke F; Los G; Slamon DJ; Konecny GE
Mol Cancer Ther; 2013 Jun; 12(6):1002-15. PubMed ID: 23729402
[TBL] [Abstract][Full Text] [Related]
15. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
16. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
Lui GYL; Shaw R; Schaub FX; Stork IN; Gurley KE; Bridgwater C; Diaz RL; Rosati R; Swan HA; Ince TA; Harding TC; Gadi VK; Goff BA; Kemp CJ; Swisher EM; Grandori C
EBioMedicine; 2020 Oct; 60():102988. PubMed ID: 32927276
[TBL] [Abstract][Full Text] [Related]
17. PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
Wang DD; Li C; Sun W; Zhang S; Shalinsky DR; Kern KA; Curtin NJ; Sam WJ; Kirkpatrick TR; Plummer R
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):89-98. PubMed ID: 27128213
[TBL] [Abstract][Full Text] [Related]
18. Rucaparib antagonize multidrug resistance in cervical cancer cells through blocking the function of ABC transporters.
Chen Z; Ling K; Zhu Y; Deng L; Li Y; Liang Z
Gene; 2020 Oct; 759():145000. PubMed ID: 32717310
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
Wang H; Ren B; Liu Y; Jiang B; Guo Y; Wei M; Luo L; Kuang X; Qiu M; Lv L; Xu H; Qi R; Yan H; Xu D; Wang Z; Huo CX; Zhu Y; Zhao Y; Wu Y; Qin Z; Su D; Tang T; Wang F; Sun X; Feng Y; Peng H; Wang X; Gao Y; Liu Y; Gong W; Yu F; Liu X; Wang L; Zhou C
J Med Chem; 2020 Dec; 63(24):15541-15563. PubMed ID: 33264017
[TBL] [Abstract][Full Text] [Related]
20. The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias.
Falzacappa MV; Ronchini C; Faretta M; Iacobucci I; Di Rorà AG; Martinelli G; Meyer LH; Debatin KM; Orecchioni S; Bertolini F; Pelicci PG
Mol Cancer Ther; 2015 Apr; 14(4):889-98. PubMed ID: 25667168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
